Sign inJoin waitlistJoin the waitlist

Meghan Sise

Assistant in Medicine · Massachusetts General Hospital

Credentials: · · · · ·

History

Massachusetts General Hospital
Present

New York Presbyterian Hospital
2012–2014
Internal Medicine
Massachusetts General Hospital
2009–2012
Columbia Univ Coll of Phys & Surgeons
2005–2009

Research

Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury
Annals of Internal Medicine · 2008 · 518 citations
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study
Journal of the American Society of Nephrology · 2020 · 303 citations
Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study
Journal of the American College of Cardiology · 2012 · 287 citations

IS
Ian Strohbehn
43 papers
Shruti Gupta
35 papers
KR
Kerry Reynolds
34 papers
HS
Harish Shanthanu Seethapathy
30 papers
DL
David Leaf
27 papers
Donald Chute
23 papers · 4 as a resident
Raymond Chung
23 papers
PH
Paul Hanna
18 papers · 12 as a fellow
QW
Qiyu Wang
18 papers · 18 as a fellow
LO
Leyre Zubiri Oteiza
17 papers · 4 as a fellow
Ryan Sullivan
16 papers
KJ
Kenar Jhaveri
14 papers

Grants

Pilot Randomized Clinical Trial of Glucocorticoid-Sparing Immunosuppressive Treatments for Immune Checkpoint Inhibitor-Associated AKI
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $312.3K · Massachusetts General Hospital
2026–2029
Rapid Diagnosis and Treatment Response Phenotyping of Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis
National Institute of Diabetes and Digestive and Kidney Diseases · R01
PI · $2.9M · Yale University
2024–2028
Mechanisms Driving Acute and Chronic Kidney Function Decline After Immune Checkpoint Inhibitor Therapy for Cancer
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $3.6M · Massachusetts General Hospital
2022–2027
Effect of Hepatitis C Virus Eradication on Chronic Kidney Disease Progression
National Institute of Diabetes and Digestive and Kidney Diseases · K23
Contact PI · $864.5K · Massachusetts General Hospital
2018–2024

Clinical trials

Infliximab for Immune Checkpoint Inhibitor Associated AKI
Principal investigator · Not yet recruiting · Phase 4
Massachusetts General Hospital
2026–2029
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Site PI · Recruiting · Phase 1, Phase 2
Cabaletta Bio
2024–2029
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2023–2029
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
Site PI · Unknown · Phase 2
Angion Biomedica Corp
2021–2023